The value of lowering cholesterol after myocardial infarction

New England Journal of Medicine

Volumn 323, Issue 16, 1990, Pages 1112-1119

  Rossouw, Jacques E ^a   Rifkind, Basil M ^a   Lewis, Barry ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOFIBRATE; NICOTINIC ACID;

CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW;

CHOLESTEROL; CLINICAL TRIALS; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MORBIDITY; MYOCARDIAL INFARCTION; RECURRENCE; RISK FACTORS;

EID: 0025043719     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199010183231606     Document Type: Article

References (64)

1. Lowering blood cholesterol to prevent heart disease. JAMA 1985; 253: 2080–6.
2. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36–69.
3. Study Group, European Atherosclerosis Society. Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. Eur Heart J 1987; 8: 77–88.
4. Study Group, European Atherosclerosis Society. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988; 9: 571–600.
5. The British Cardiac Society Working Group on Coronary Prevention: conclusions and recommendations. Br Heart J 1987; 57: 188–9.
6. Committee on Diet and Health, Food and Nutrition Board, Commission on Life Sciences, National Research Council. Diet and health: implications for reducing chronic disease risk. Washington, D.C.: National Academy Press, 1989.
7. Secondary prevention of coronary disease with lipid-lowering drugs. Lancet 1989; 1: 473–4.
8. Siegel D, Grady D, Browner WS, Hulley SB. Risk factor modification after myocardial infarction. Ann Intern Med 1988; 109: 213–8.
9. Evans AE. Secondary prevention after myocardial infarction. Lancet 1986; 2: 150–1.
10. Crouse JR III, Ryu JE, Kahl FR. Changes in pharmacologic treatment of hyperlipidemia. Am J Prev Med 1989; 5: 90–4.
11. Watt P, Becker DM, Salaeita K, Pearson TA. Hypercholesterolemia in patients undergoing coronary bypass surgery: are they aware, under treatment, and under control? Heart Lung 1988; 17: 205–8.
12. Hoad NA. Searching for hyperlipidaemia in patients with coronary artery bypass grafts. Lancet 1989; 1: 968–9.
13. Shaper AG, Pocock SJ, Walker M, Phillips AN, Whitehead TP, Macfarlane PW. Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. J Epidemiol Community Health 1985; 39: 197–209.
14. Gordon DJ, Ekelund LG, Karon JM, et al. Predictive value of the exercise tolerance test for mortality in North American men: the Lipid Research Clinics Mortality Follow-up Study. Circulation 1986; 74: 252–61.
15. Rose G, Hamilton PS, Keen H, Reid DD, McCartney P, Jarrett RJ. Myocardial ischaemia, risk factors and death from coronary heart-disease. Lancet 1977; 1: 105–9.
16. Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: an epidemiologic investigation of cardiovascular disease. Section 35. Survival following initial cardiovascular events: thirty year follow-up. Washington, D.C.: Government Printing Office, 1988. (NIH publication no. 88–2969.)
17. Trial of clofibrate in the treatment of ischaemic heart disease: five-year study by a group of physicians of the Newcastle upon Tyne region. BMJ 1971; 14: 767–75.
18. Ischaemic heart disease: a secondary prevention trial using clofibrate: report by a research committee of the Scottish Society of Physicians. BMJ 1971; 4: 775–84.
19. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360–81.
20. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405–18.
21. A Research Committee. Low-fat diet in myocardial infarction: a controlled trial. Lancet 1965; 2: 501–4.
22. Controlled trial of soya-bean oil in myocardial infarction: report of research committee to the Medical Research Council. Lancet 1968; 2: 693–700.
23. Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction: a controlled clinical trial. Acta Med Scand Suppl 1966; 466: 1–92.
24. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64.
25. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45.
26. A Cooperative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators. Br Heart J 1978; 40: 1069–118.
27. Dayton S, Pearce ML, Hashimoto S, Dixon WJ, Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969; 40: Suppl II: II-1–II-63.
28. Coronary Drug Project Research Group. Natural history of myocardial infarction in the Coronary Drug Project: long-term prognostic importance of serum lipid levels. Am J Cardiol 1978; 42: 489–98.
29. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of randomized trials. Prog Cardiovasc Dis 1985; 27: 355–71.
30. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988; 260: 2259–63.
31. The Multicenter Diltiazem Postinfarction Trial research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–-92.
32. Schlant RC, Forman S, Stamler J, Canner PL. The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men: the 5-year findings of the Coronary Drug Project. Circulation 1982; 66: 401–14.
33. Moss AJ, Benhorin J. Prognosis and management after a first myocardial infarction. N Engl J Med 1990; 322: 743–53.
34. Goldbourt U, Cohen L, Neufeld HN. High density lipoprotein cholesterol: prognosis after myocardial infarction: the Israeli Ischaemic Heart Disease Study. Int J Epidemiol 1986; 15: 51–5.
35. Heliövaara M, Karvonen MJ, Punsar S, Haapakoski J. Importance of coronary risk factors in the presence or absence of myocardial ischemia. Am J Cardiol 1982; 50: 1248–52.
36. Wong ND, Cupples LA, Ostfeld AM, Levy D, Kannel WB. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Am J Epidemiol 1989; 130: 469–80.
37. Jenkins CD, Zyzanski SJ, Rosenman RH. Risk of new myocardial infarction in middle-aged men with manifest coronary heart disease. Circulation 1976; 53: 342–7.
38. Frost PH, Verter J, Miller D. Serum lipids and lipoproteins after myocardial infarction: associations with cardiovascular mortality and experience in the Aspirin Myocardial Infarction Study. Am Heart J 1987; 113: 1356–64.
39. Ulvenstam G, Bergstrand R, Johansson S, et al. Prognostic importance of cholesterol levels after myocardial infarction. Prev Med 1984; 13: 355–66.
40. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700–7.
41. Jafri SM, Tilley BC, Peters R, Schultz LR, Goldstein S. Effects of cigarette smoking and propranolol in survivors of acute myocardial infarction. Am J Cardiol 1990; 65: 271–6.
42. Khaw K-T, Barrett-Connor E. Prognostic factors for mortality in a population-based study of men and women with a history of heart disease. J Cardiopulmonary Rehabil 1986; 6: 474–80.
43. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823–8.
44. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–48.
45. National Heart, Lung, and Blood Institute. Data fact sheet: morbidity from coronary heart disease in the United States. Bethesda. Md.: NHLBI Education Program Information Center, June 1990.
46. Abernathy JR, Thorn MD, Trobaugh GB, et al. Prevalence of ischemic resting and stress electrocardiographic abnormalities and angina among 40- to 59- year-old men in selected U.S. and U.S.S.R. populations. Circulation 1988; 77: 270–8.
47. Shaper AG, Cook DG, Walker M, Macfarlane PW. Prevalence of ischaemic heart disease in middle aged British men. Br Heart J 1984; 51: 595–605.
48. Pekkanen J, Nissinen A, Puska P, Punsar S, Karvonen MJ. Risk factors and 25 year risk of coronary heart disease in a male population with a high incidence of the disease: the Finnish cohorts of the seven countries study. BMJ 1989; 299: 81–5.
49. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 313–24.
50. Arntzenius achéal, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis: the Leiden Intervention Trial. N Engl J Med 1985; 312: 805–11.
51. Nikkila EA, Viikinkoski P, Valle M, Frick MH. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven-year prospective angiographic study. BMJ 1984; 289: 220–3.
52. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233–40.
53. Brown BG, Lin JT, Schaefer SM, Kaplan CA, Dodge HT, Albers JJ. Niacin or lovastatin, combined with colestipol, regress coronary atherosclerosis and prevent clinical events in men with elevated apolipoprotein B. Circulation 1989; 80: Suppl II: II-266. abstract.
54. Rose G, Shipley M. Effects of coronary risk reduction on the pattern of mortality. Lancet 1990; 335: 275–7.
55. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245–55.
56. Leren P. The Oslo Diet-Heart Study: eleven-year report. Circulation 1970; 42: 935–42.
57. Hjermann I, Holme I, Leren P. Oslo Diet and Antismoking Trial: results after 102 months. Am J Med 1986; 80: 7–11.
58. The Multiple Risk Factor Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA 1990; 263: 1795–801.
59. Fries JF, Green LW, Levine S. Health promotion and the compression of morbidity. Lancet 1989; 1: 481–3.
60. Wittels EH, Hay JW, Gotto AM Jr. Medical costs of coronary artery disease in the United States. Am J Cardiol 1990; 65: 432–40.
61. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24–33.
62. Miller M, Mead LA, Kwiterovitch PO Jr, Pearson TA. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol 1990; 65: 1–5.
63. Kallio V, Hämäläinen H, Hakkila J, Luurila OJ. Reduction in sudden deaths by a multifactorial intervention programme after acute myocardial infarction. Lancet 1979; 2: 1091–4.
64. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336: 129–33.